# Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19

> **NCT05908071** · PHASE3 · UNKNOWN · sponsor: **Shenzhen Kexing Pharmaceutical Co., Ltd.** · enrollment: 1200 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** SHEN26 capsule
- **DRUG:** SHEN26 placebo

## Key facts

- **NCT ID:** NCT05908071
- **Lead sponsor:** Shenzhen Kexing Pharmaceutical Co., Ltd.
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-13
- **Primary completion:** 2024-05
- **Final completion:** 2024-07
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05908071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05908071, "Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05908071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*